Matt Ralph Grimmer
Affiliations: | 2014 | Genetics | University of California, Davis, Davis, CA |
Google:
"Matt Grimmer"Mean distance: 10.81 | S | N | B | C | P |
Parents
Sign in to add mentor| Joseph Costello | grad student | (Neuro-oncology Tree) | ||
| Peggy J. Farnham | grad student | 2014 | UC Davis | |
| (Genome-wide functional analysis of epigenetic toggle switches.) | ||||
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Mathur R, Zhang Y, Grimmer MR, et al. (2020) MGMT promoter methylation level in newly diagnosed low-grade glioma is a predictor of hypermutation at recurrence. Neuro-Oncology |
| Oberheim Bush NA, Yu Y, Villanueva-Meyer J, et al. (2020) Temozolomide-induced hypermutation is associated with high-grade transformation, distant recurrence, and reduced survival after transformation in initially low-grade IDH-mutant diffuse gliomas. Journal of Clinical Oncology. 38: 2506-2506 |
| Barthel FP, Johnson KC, Varn FS, et al. (2019) Longitudinal molecular trajectories of diffuse glioma in adults. Nature |
| Zhang M, Hilz S, Martin M, et al. (2019) IMMU-11. SPATIOTEMPORAL IMMUNOGENOMIC ANALYSIS OF THE T-CELL REPERTOIRE IN IDH-MUTANT LOWER GRADE GLIOMAS Neuro-Oncology. 21: vi121-vi121 |
| Mathur R, Zhang Y, Grimmer M, et al. (2019) GENE-35. MGMT PROMOTER METHYLATION IN NEWLY DIAGNOSED LGG AS A POTENTIAL BIOMARKER FOR TMZ-ASSOCIATED HYPERMUTATION AT RECURRENCE Neuro-Oncology. 21: vi105-vi105 |
| Choi S, Yu Y, Grimmer MR, et al. (2018) Temozolomide-associated Hypermutation in Gliomas. Neuro-Oncology |
| Grimmer MR. (2018) Abstract LB-376: Clinico-genomic analysis of temozolomide-induced hypermutation in both molecular subtypes of IDH-mutant glioma Cancer Research. 78 |
| Yu Y, Hilz S, Grimmer M, et al. (2018) PATH-29. CLINICAL SIGNIFICANCE OF TEMOZOLOMIDE-INDUCED SOMATIC HYPERMUTATION IN INITIALLY LOW-GRADE IDH-MUTANT DIFFUSE GLIOMAS Neuro-Oncology. 20: vi164-vi165 |
| Campbell BB, Light N, Fabrizio D, et al. (2017) Comprehensive Analysis of Hypermutation in Human Cancer. Cell |
| Jones L, Mazor T, Grimmer M, et al. (2017) TMOD-23. ESTABLISHMENT AND CHARACTERIZATION OF IDH1-MUTANT HYPERMUTATED GLIOMA CELL LINES Neuro-Oncology. 19: vi259-vi259 |